• Positive results from ongoing Phase 1b trial of azer-cel, with 4 complete responses out of 7 evaluable patients
• Received Fast Track Designation from FDA for azer-cel to treat relapsed/refractory DLBCL
• First Australian patient dosed with azer-cel at Royal Prince Alfred Hospital

Imugene Limited, a clinical-stage immuno-oncology company, reported its quarterly activities and cash flow for the period ended 31 March 2025. The company highlighted positive results from the ongoing Phase 1b clinical trial evaluating azer-cel, an allogeneic off-the-shelf CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Two new complete responses were reported, bringing the total to four complete responses out of seven evaluable patients in Cohort B, translating to a 57% complete response rate. Imugene also received Fast Track Designation from the US FDA for the treatment of relapsed or refractory DLBCL with azer-cel, and dosed the first Australian patient in the Phase 1b trial at the Royal Prince Alfred Hospital in Sydney. In the company's onCARlytics program, the first dose level was cleared in the intravenous (IV) combination arm of the OASIS trial, targeting adult patients with advanced or metastatic solid tumours. Imugene also reported receiving patent allowances and grants for its OnCARlytics and PD1-Vaxx technologies in China, India, and Australia. Corporately, the company appointed Darren Keamy as Chief Financial Officer and Company Secretary. Financially, Imugene received A$20 million from the issuance of convertible notes and A$11.7 million in R&D tax refunds, ending the quarter with A$36.25 million in cash and equivalents.